ArticleBMC infectious diseases2025
Histoplasmosis in India: clinical insights from a tertiary care hospital.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHistoplasma capsulatum, a dimorphic fungus, is a significant cause of endemic mycosis, particularly in immunocompromised individuals. While considered endemic to the Gangetic Plains in India, reports from nonendemic regions have been increasing. This study aims to enhance the understanding and diagnosis of histoplasmosis by describing cases from a tertiary care hospital in New Delhi, India.
methodsA retrospective study involving adult patients diagnosed with histoplasmosis was conducted at Sir Ganga Ram Hospital, New Delhi, India, from 1st July 2019 to 31st March 2024. Clinical data were extracted from the hospital’s electronic medical records and analysed.
resultsEleven patients with a mean age of 48.4 years were identified. Of the patients, 10 (90.9%) were male. Except for one patient, all had identifiable risk factors such as immunosuppressive therapy, HIV (human immunodeficiency virus), or diabetes. Common symptoms included fever (90.9%) and weight loss (72.7%). Hematological abnormalities such as anemia and leukopenia (36.3%) and radiological findings of splenomegaly (72.7%) and hepatomegaly (63.6%) were most common. Complications such as hemophagocytic lymphohistiocytosis (HLH) and multiple organ dysfunction syndrome (MODS) occurred in 27.2% of patients, with a mortality rate of 18.18%.
conclusionOur study highlights that, in India, histoplasmosis is frequently detected in its advanced disseminated form, particularly among immunocompromised patients, rather than at an early acute pulmonary stage. This delay is compounded by its clinoco-radiological resemblance to infections like tuberculosis and the limited availability of rapid diagnostic tools, often requiring invasive procedures. An enhanced understanding of histoplasmosis could help mitigate misdiagnosis and lead to better treatment outcomes. These findings call for increased clinical awareness amongst clinicians and early screening in at-risk groups, supported by expanded research to strengthen epidemiological data and establish clear diagnostic guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.